Renin Angiotensin System Blockade in Renal Transplant Patients With Presence of PECs in Urine
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
By means of a personalized medicine strategy, investigators are going to evaluate if the
treatment with an angiotensin II receptor antagonist (ARAII) in renal transplant patients
with the presence of renal progenitor cells (PECs) in the urine is able to prevent the
expected loss of glomerular filtration (GFR) observed in this subgroup of patients. In
addition, investigators intend to deepen the mechanisms of glomerular damage and glomerular
repair involved in the process of chronic allograft damage.